Better Diagnostics, Better Life
AnchorDx, established in Guangzhou International Bio Island in 2015, has set up R&D centers in China and the United States. It is committed to the R&D, production and sales of early cancer screening and diagnosis products using internationally leading high-throughput methylation sequencing and is able to provide the corresponding detection services. The founder, Dr. Jianbing Fan, is an international leading figure in the field of genetic testing, was included in the 2021 "World's Top 2% Scientists - Lifetime Scientific Impact List" and has 30 years of experience in the development of human genomics, Microarrays and high-throughput sequencing technologies.
AnchorDx is a pioneer of applying ctDNA high-throughput methylation sequencing technology in early detection of tumors in China. Focusing on two major lines: "a tube of blood" and "a tube of urine", AnchorDx has developed products covering more than 70% of high-incidence cancers, such as lung cancer, breast cancer, digestive system cancer and urinary system cancer, throughout the process of early cancer screening, early diagnosis, recurrence monitoring and companion diagnostics.
In addition, AnchorDx also has independently developed a big data and AI platform centered on early screening, early diagnosis and treatment of lung cancer. By now, AnchorDx has applied for 82 patents at home and abroad (32 patented), all of which are proprietary and original. Its scientific research findings have been included in many important international academic journals, laying an important foundation for global commercialization.
in technology development
“a tube of blood” and “a tube of urine”
of high-incidence cancers
people benefited
Better Diagnostics, Better Life
-
1982~1985Studied with a dream
1982, graduated from Fudan University
1985, conferred with a Master's Degree by Shanghai Institute of Cell Biology, CAS
-
1986~1996Studied genomics abroad
1986~1992, conferred with a Doctoral Degree in human genetics by Columbia University USA
1992~1996, carried out postdoctoral research at the human genome centers of UCSF and Stanford University and independently led the research teams to conduct the technical work related to genomic research
-
1996~2015Dug into research and paid attention to accumulation of practical experience
1996, after completing the postdoctoral research, Dr. Fan worked for biochip giant Affymetrix. As a key member, he led the development of technologies/products including SNP Genotyping, laying a solid foundation for genome wide association study (GWAS)
1999, he was invited to join Illumina as a senior CTO and a founding employee (job number 23), led the R&D of a series of technologies/products including BeadArray technology and led the team to complete the clinical certification of the world’s first high-throughput sequencing platform by US FDA
-
2015~NowReturned to China and joined the precision medicine industry
2015, returned to China and established AnchorDx to start a new journey of cancer screening based on gene sequencing
2016, a finalist and guest judge of "National Major Talent Project"
2022, included in "Global Top 100,000 Scientists" and ranked 151st in the sector of Chinese clinical medicine (biology)
2022, included in World's Top 2% Scientists – "Lifetime Scientific Impact List"
2022, included in Elsevier "Highly Cited Chinese Researchers" list
2023, selected into the Elsevier 2022 list of "Highly Cited Scholars in China"
The core R&D team members of AnchorDx are all from world-class universities. They have many years of experience in analysis of technologies related to precision medicine and bioinformatics, have gone in for R&D work in Illumina, a leading enterprise in the industry, for many years and always stay at the forefront of technology.
Responsible for the research and development of technologies and products
A global leader in genetic technology and former chief scientist of Illumina
In the previous 20+ years, Marina has developed a series of technologies and products that have had a significant influence on the genomic industry.
.png)
Responsible for the research and development of technologies and products for diagnostics
Responsible for the optimization of liquid biopsy assay at Illumina, which was later used at Grail
Responsible for companion diagnostics assay development at Thermo Fisher
Postdoctoral fellow at Washington State University and Sandia National Laboratories (Department of Energy)
Milestones
Honors & Qualification
Investor Relations
AnchorDx has completed series A, A+ and C financing in total of US$83 million; the cooperation of multiple international renowned investment institutions and industry leading enterprises indicates that the high-throughput sequencing technology and products of AnchorDx have a high growth potential, a broad development prospect and a significant market value and business potential.
Production & Quality
AnchorDx has built a GMP standard workshop of 1000 square meters, including a 10,000-grade workshop, a microbial limit room, a cell culture room and a 100,000-grade diagnostic reagent workshop.
In addition, it also has built an independent production quality control center, R&D laboratory and clinical testing center, each about 1,000 square meters, which can meet the requirements of NGS, PCR and other platforms for development, production and quality inspection of technologies and products.
The company has established a quality management system (QMS) in accordance with ISO13485 and the Good Manufacturing Practice for Medical Devices and passed the international certification of ISO13485 quality system.
-995.jpg)
